Claims:

1. Compound of the formula



(I)

where

R_1 is a) hydrogen, amino or hydroxyl; or

is b) C_1-C_8-alkyl, C_3-C_8-cycloalkyl, C_1-C_8-alkanoyl, C_1-C_8-alkoxycarbonyl, aryl-C_0-C_4-alkyl or heterocyclyl-C_0-C_4-alkyl, which radicals may be substituted by 1-4, C_1-C_8-alkyl, halogen, cyano, oxide, oxo, trifluoromethyl, C_1-C_8-alkoxy, C_1-C_8-alkoxycarbonyl, aryl or heterocyclyl;

R_2 is a) C_1-C_8-alkyl, C_3-C_8-cycloalkyl, C_1-C_8-alkylsulphonyl, C_3-C_8-cycloalkylsulphonyl, aryl-C_0-C_8-alkylsulphonyl, heterocyclylsulphonyl, C_3-C_8-cycloalkyl-C_1-C_8-alkanoyl, aryl-C_1-C_8-alkanoyl, aryl-C_3-C_8-cycloalkanoyl, C_1-C_8-alkanoyl, C_1-C_8-alkoxycarbonyl, optionally N-mono- or N,N-di-C_1-C_8-alkylated carbamoyl-C_0-C_8-alkyl, aryl-C_0-C_4-alkyl or heterocyclyl-C_0-C_4-alkyl, which radicals may be substituted by 1-4 C_1-C_8-alkyl, C_3-C_{12}-cycloalkyl, C_3-C_8-cycloalkoxy, amino, C_1-C_6-alkylamino, di-C_1-C_6-alkylamino, C_1-C_6-alkanoylamino, C_1-C_6-alkoxycarbonylamino, halogen, oxo, cyano, hydroxyl, oxide, trifluoromethyl, C_1-C_8-alkoxy, optionally N-mono- or N,N-di-C_1-C_8-alkylated carbamoyl-C_0-C_8-alkyl, optionally esterified carboxyl, C_1-C_6-alkylenedioxy, aryl or heterocyclyl; or

is b) together with R_1 and the nitrogen atom to which they are bonded a saturated or partly unsaturated 4-8-membered heterocyclic ring which may contain an additional nitrogen, oxygen or sulphur atom or a -SO- or -SO2- group, in which case the additional nitrogen atom may optionally be substituted by C_1-C_8-alkyl, C_1-C_8-alkanoyl, C_1-C_8-alkoxycarbonyl, aryl or heterocyclyl radicals, and this heterocyclic ring may be part of a bicyclic or tricyclic ring system having a total of up to 16 members and the second ring may also contain a nitrogen, oxygen or sulphur atom or a -SO- or -SO2- group, and the nitrogen atom in the second ring may optionally be substituted by C_1-C_8-alkyl, C_1-C_8-alkanoyl, C_1-C_8-alkoxycarbonyl, aryl or heterocyclyl radicals and all ring systems mentioned may be substituted by 1-4 C_1-C_8-alkyl, C_3-C_8-cycloalkyl, C_1-C_8-alkylsulphonyl, C_3-C_8-cycloalkylsulphonyl, aryl-C_0-C_8-alkylsulphonyl,

heterocyclylsulphonyl, C_3-C_8-cycloalkyl-C_1-C_8-alkanoyl, aryl-C_1-C_8-alkanoyl, C_1-C_8-alkanoyl, C_1-C_8-alkoxycarbonyl, optionally N-mono- or N,N-di-C_1-C_8-alkylated carbamoyl-C_0-C_8-alkyl, halogen, hydroxyl, oxide, oxo, trifluoromethyl, C_1-C_8-alkoxy, C_1-C_8-alkoxy-C_1-C_8-alkoxy, C_1-C_8-alkoxy-C_1-C_8-alkyl, C_1-C_8-alkoxycarbonylamino, C_1-C_8-alkanoylamino, C_1-C_8-alkylamino, N,N-di-C_1-C_8-alkylamino, aryl-C_0-C_4-alkyl, aryloxy-C_0-C_4-alkyl, aryl-C_0-C_4-alkyl-C_1-C_8-alkoxy, aryloxy-C_0-C_4-alkyl-C_1-C_8-alkoxy, heterocyclyl-C_0-C_4-alkyl, heterocyclyloxy-C_0-C_4-alkyl, heterocyclyl-C_0-C_4-alkyl-C_1-C_8-alkoxy or heterocyclyloxy-C_0-C_4-alkyl-C_1-C_8-alkoxy;
R_3 is hydrogen, C_1-C_8-alkyl, C_1-C_8-alkoxycarbonyl or C_1-C_8-alkanoyl;
R_4 is hydrogen, C_1-C_8-alkyl, C_1-C_8-alkoxycarbonyl or C_1-C_8-alkanoyl;
R_5 are each independently hydrogen or C_1-C_8-alkyl or, together with the carbon atom to which they are bonded, are a C_3-C_8-cycloalkylidene radical;
R_6 is one oxygen atom or two hydrogen atoms;
R is optionally substituted arylamino, N-aryl-N-((lower alkoxy)(lower alkyl))amino, N-aryl-N-aryl(lower alkyl)amino or heterocyclyl bonded via a ring nitrogen atom;
or salt or prodrug thereof, or where one or more atoms are replaced by their stable, non-radioactive isotopes.

2. Compound according to Claim 1, where
R_1 a) is hydrogen; or
is b) C_1-C_8-alkyl, C_3-C_8-cycloalkyl, C_1-C_8-alkanoyl, C_1-C_8-alkoxycarbonyl, aryl-C_0-C_4-alkyl or heterocyclyl-C_0-C_4-alkyl, which radicals may be substituted by 1 - 4 C_1-C_8-alkyl, halogen, cyano, oxide, oxo, trifluoromethyl, C_1-C_8-alkoxy, C_1-C_8-alkoxycarbonyl, aryl or heterocyclyl;
R_2 is a) C_1-C_8-alkyl, C_3-C_8-cycloalkyl, C_1-C_8-alkylsulphonyl, C_3-C_8-cycloalkylsulphonyl, aryl-C_0-C_8-alkylsulphonyl, heterocyclylsulphonyl, C_3-C_8-cycloalkyl-C_1-C_8-alkanoyl, aryl-C_1-C_8-alkanoyl, aryl-C_3-C_8-cycloalkanoyl, C_1-C_8-alkanoyl, C_1-C_8-alkoxycarbonyl, optionally N-mono- or N,N-di-C_1-C_8-alkylated carbamoyl-C_0-C_8-alkyl, aryl-C_0-C_4-alkyl or heterocyclyl-C_0-C_4-alkyl, which radicals may be substituted by 1 - 4 C_1-C_8-alkyl, C_3-C_8-cycloalkyl, C_3-C_8-cycloalkoxy, amino, C_{1-6}-alkylamino, di-C_{1-6}-alkylamino, C_0-C_6-alkylcarbonylamino, C_1-C_6-alkoxycarbonylamino, halogen, oxo, cyano, hydroxyl, oxide, trifluoromethyl, C_1-C_8-alkoxy, optionally N-mono- or N,N-di-C_1-C_8-alkylated carbamoyl-C_0-C_8-alkyl, optionally esterified carboxyl, C_{1-6}-alkylenedioxy, aryl or heterocyclyl; or
is b) together with R_1 and the nitrogen atom to which they are bonded, a saturated or partly unsaturated 4 - 8-membered heterocyclic ring which may contain an additional nitrogen, oxygen or sulphur atom or a -SO- or –SO2- group, in which case the additional nitrogen atom may optionally be substituted by C_1-C_8-alkyl, C_1-C_8-alkanoyl, C_1-C_8-alkoxycarbonyl, aryl or

heteroaryl radicals, and this heterocyclic ring may be part of a bicyclic or tricyclic ring system having a total of up to 16 members and the second ring may also contain a nitrogen, oxygen or sulphur atom or a -SO- or -SO2- group, and the nitrogen atom in the second ring may optionally be substituted by C_1-C_8-alkyl, C_1-C_8-alkanoyl, C_1-C_8-alkoxycarbonyl, aryl or heterocyclyl radicals, and all ring systems mentioned may be substituted by 1 - 4 C_1-C_8-alkyl, halogen, hydroxyl, cyano, oxide, oxo, trifluoromethyl, C_1-C_8-alkoxy, C_1-C_8-alkoxy-C_1-C_8-alkoxy, C_1-C_8-alkoxycarbonylamino, C_0-C_8-alkylcarbonylamino, C_1-C_8-alkylamino, N,N-di-C_1-C_8-alkylamino, aryl-C_0-C_4-alkyl, aryloxy-C_0-C_4-alkyl, aryl-C_0-C_4-alkyl-C_1-C_8-alkoxy, aryloxy-C_0-C_4-alkyl-C_1-C_8-alkoxy, heterocyclyl-C_0-C_4-alkyl, heterocyclyloxy-C_0-C_4-alkyl, heterocyclyl-C_0-C_4-alkyl-C_1-C_8-alkoxy or heterocyclyloxy-C_0-C_4-alkyl-C_1-C_8-alkoxy;
R_3 is hydrogen, C_1-C_8-alkyl, C_1-C_8-alkoxycarbonyl or C_1-C_8-alkanoyl;
R_4 is hydrogen, C_1-C_8-alkyl, C_1-C_8-alkoxycarbonylor C_1-C_8-alkanoyl;
R_5 are each independently hydrogen or C_1-C_8-alkyl,
R_6 is oxygen,
R is arylamino, N-aryl-N-((lower alkoxy)(lower alkyl))amino, N-aryl-N-aryl(lower alkyl)amino or heterocyclyl bonded via a ring nitrogen atom, in which case the heterocyclyl mentioned, apart from the ring nitrogen atom via which it is bonded, may contain further ring heteroatoms selected from oxygen, nitrogen, nitrogen substituted by lower alkyl, lower alkanoyl, (lower alkane)sulphonyl or (lower alkoxy)carbonyl, sulphur, and sulphur bonded to 1 or 2 oxygen atoms,
or salt or prodrug thereof, or where one or more atoms are replaced by their stable, non-radioactive isotopes.

3. Compound according to Claim 1 or 2 of the formula I, where R is a group of the formula



(Ia) or



(Ib)

in which
A is a direct bond, methylene, dimethylene, imino, oxy or thio,

R_7 is C_1-C_4-alkoxy-C_1-C_4-alkyl, such as methoxy- or propyloxymethyl, C_3-C_5-alkenyloxy-C_1-C_4-alkyl, such as allyloxymethyl, C_1-C_4-alkoxy-C_1-C_4-alkoxy-C_1-C_4-alkyl, such as

methoxymethoxymethyl or 2-methoxyethoxymethyl, C_1-C_4-alkoxycarbonylamino-C_1-C_4-alkyl, such as methoxy- or ethoxycarbonylaminomethyl, C_1-C_4-alkoxyimino-C_1-C_4-alkyl, such as methoxyiminomethyl, phenyl, C_1-C_4-alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl or isopropyloxycarbonyl, cyano, carbamoyl, N-C_1-C_4-alkylcarbamoyl, such as N-methylcarbamoyl, N-ethylcarbamoyl or N-butylcarbamoyl, C_1-C_4-alkoxy-C_1-C_4-alkylcarbamoyl, such as N-(2-methoxyethyl)carbamoyl, C_1-C_4-alkoxy such as propyloxy, C_1-C_4-alkoxy-C_1-C_4-alkoxy such as methoxymethoxy or 2-methoxyethoxy, C_1-C_8-alkanoyloxy such as acetoxy, benzoyloxy, N-C_1-C_4-alkylcarbamoylamino, such as N-methylcarbamoylamino, C_1-C_4-alkanoylamino, such as acetylamino, C_1-C_4-alkoxycarbonylamino, such as methoxycarbonylamino, 3- to 6-membered cycloalkylcarbonylamino, such as cyclopropylcarbonylamino, C_1-C_4-alkoxy-C_1-C_4-alkanoylamino, such as methoxyacetylamino, or 5- or 6-membered N,N-(1-oxo(lower alkylene))amino or N,N-(1-oxo-2-oxa(lower alkylene))amino, such as 2-oxopyrrolidin-1-yl or 2-oxooxazolidin-3-yl, N-C_1-C_4-alkylcarbamoylamino, such as methylcarbamoylamino,
R_8 is hydrogen, but may also be C_1-C_4-alkyl such as methyl,
R_9 is hydrogen or halogen and

R_{10} is C_1-C_4-alkoxy-C_1-C_4-alkyl, such as methoxy-C_1-C_4-alkyl, ethoxy-C_1-C_4-alkyl, propyloxy-C_1-C_4-alkyl, isopropyloxy-C_1-C_4-alkyl, butyloxy-C_1-C_4-alkyl, isobutyloxy-C_1-C_4-alkyl, sec-butyloxy-C_1-C_4-alkyl or tert-butyloxy-C_1-C_4-alkyl, where C_1-C_4-alkyl is, for example, ethyl, propyl or butyl, and is in particular 3-methoxypropyl.

4. Compound according to Claim 1 of the formula



(Ic)

where R, R_1, R_2, R_3, R_4, R_5 and R_8 are each as defined in Claim 1 or salt thereof, in particular pharmaceutically usable salt thereof.

5. Compound according to Claim 1 of the formula



(Id)

where

A is methylene, oxy or thio,

R_1 is a) hydrogen; or

is b) C_1-C_8-alkyl or C_3-C_8-cycloalkyl;

R_2 is a) C_1-C_8-alkyl, C_3-C_8-cycloalkyl, C_1-C_8-alkanoyl, heterocyclyl-C_1-C_8-alkanoyl, C_3-C_{12}-cycloalkyl-C_1-C_8-alkanoyl or aryl-C_1-C_8-alkanoyl, which radicals may be substituted by 1 - 4 C_1-C_8-alkyl, C_3-C_8-cycloalkyl, C_3-C_8-cycloalkoxy, C_{1-6}-alkylamino, cyano, halogen, hydroxyl, oxide, C_0-C_6-alkylcarbonylamino, C_1-C_8-alkoxy, oxo, trifluoromethyl or aryl; or

b) together with R_1 and the nitrogen atom to which they are bonded, is a saturated or partly unsaturated, 4 - 8-membered heterocyclic ring which may contain an additional nitrogen or oxygen atom, in which case the additional nitrogen atom may optionally be substituted by C_1-C_8-alkyl or C_1-C_8-alkanoyl, and this heterocyclic ring may be part of a bicyclic or tricyclic ring system having a total of up to 16 members, and the second ring may also contain a nitrogen or oxygen atom, in which case the nitrogen atom of the second ring may optionally be substituted by C_1-C_8-alkyl or C_1-C_8-alkanoyl, and all ring systems mentioned may be substituted by 1 - 4 C_1-C_8-alkyl, hydroxyl, cyano, oxide, oxo, C_1-C_8-alkoxy, C_1-C_8-alkoxy-C_1-C_8-alkoxy, C_0-C_8-alkylcarbonylamino, C_1-C_8-alkoxycarbonylamino or aryloxy-C_0-C_4-alkyl-C_1-C_8-alkoxy;

R_3 is hydrogen or –(C=O)-C_1-C_4-alkyl;

R_4 is hydrogen;

R_5 are each independently C_1-C_4-alkyl, such as methyl,

R_7 is C_1-C_4-alkoxycarbonylamino such as methoxycarbonylamino, ethoxycarbonylamino, propyloxycarbonylamino, isopropyloxycarbonylamino or butyloxycarbonylamino, C_1-C_4-alkoxy-C_1-C_4-alkoxy-C_1-C_4-alkyl, such as methoxy-C_1-C_4-alkoxy-C_1-C_4-alkyl, ethoxy-C_1-C_4-alkoxy-C_1-C_4-alkyl, propyloxy-C_1-C_4-alkoxy-C_1-C_4-alkyl, isopropyloxy-C_1-C_4-alkoxy-C_1-C_4-alkyl or butyloxy-C_1-C_4-alkoxy-C_1-C_4-alkyl, where C_1-C_4-alkoxy is, for example, methoxy, ethoxy,

propyloxy or butyloxy, and C_1-C_4-alkyl is, for example, methyl, ethyl, propyl or butyl, in particular methoxymethoxymethyl, 2-methoxyethoxymethyl or 3-methoxypropyloxymethyl, C_1-C_4-alkoxy-C_1-C_4-alkyl, such as methoxy-C_1-C_4-alkyl, ethoxy-C_1-C_4-alkyl, propyloxy-C_1-C_4-alkyl, isopropyloxy-C_1-C_4-alkyl, butyloxy-C_1-C_4-alkyl, isobutyloxy-C_1-C_4-alkyl, sec-butyloxy-C_1-C_4-alkyl or tert-butyloxy-C_1-C_4-alkyl, where C_1-C_4-alkyl is, for example, methyl, ethyl, propyl or butyl, in particular ethoxymethyl or 2-methoxyethyl, or N-C_1-C_4-alkylcarbamoyl, such as N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl or N-butylcarbamoyl, or salt thereof, in particular a pharmaceutically usable salt thereof.

6. Compound according to one of Claims 1 - 5 for use in a process for the therapeutic treatment of the human or animal body.

7. Pharmaceutical preparation comprising, as an active pharmaceutical ingredient, a compound according to one of Claims 1 - 5 in free form or as a pharmaceutically usable salt.

8. Use of a compound according to one of Claims 1 - 5 for the preparation of a pharmaceutical preparation with renin-inhibiting action.

9. Use of a compound according to one of Claims 1 - 5 for the preparation of a pharmaceutical preparation for the treatment or prevention of hypertension, heart failure, glaucoma, cardiac infarction, kidney failure or restenosis.